Deutsch English Français

Contact

EP3643713

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP3643713

EP3643713 - HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF [Right-click to bookmark this link]
Status	Examination is in progress Status updated on 21.01.2022 Database last updated on 13.07.2024
Former	Request for examination was made Status updated on 06.11.2020
Former	The application has been published Status updated on 27.03.2020
Most recent event Tooltip	27.10.2023	New entry: Renewal fee paid
Applicant(s)	For all designated states iOmx Therapeutics AG Fraunhoferstrasse 13 82152 Martinsried / DE
	[2020/18]
Inventor(s)	01 / Sennhenn, Peter c/o iOmx Therapeutics AG Fraunhoferstrasse 13 82152 Martinsried / DE
	02 / Meier-Ewert, Sebastian c/o iOmx Therapeutics AG Fraunhoferstrasse 13 82152 Martinsried / DE
	03 / Khandelwal, Nisit c/o iOmx Therapeutics AG Fraunhoferstrasse 13 82152 Martinsried / DE
	04 / Bancroft, David c/o iOmx Therapeutics AG Fraunhoferstrasse 13 82152 Martinsried / DE
	[2020/18]
Representative(s)	Kuttenkeuler, David SKM-IP PartGmbB Oberanger 45 80331 München / DE
	[N/P]
Former [2020/18]	Müller, Christian Stefan Gerd ZSP Patentanwälte PartG mbB Hansastraße 32 80686 München / DE
Application number, filing date	18202164.2	23.10.2018
	[2020/18]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	EP3643713
	Date:	29.04.2020
	Language:	EN
	[2020/18]
Search report(s)	(Supplementary) European search report - dispatched on:	EP	09.08.2019
Classification	IPC:	C07D417/14, A61P35/00, A61K31/506	[2020/18]
	CPC:	C07D417/14 (EP,IL,KR,US); A61K31/506 (KR); A61P35/00 (KR,US)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/50]
Former [2020/18]	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Extension states	BA	Not yet paid
	ME	Not yet paid
Validation states	KH	Not yet paid
	MA	Not yet paid
	MD	Not yet paid
	TN	Not yet paid
Title	German:	HETEROCYCLISCHE KINASEHEMMER UND VERWENDUNGEN DAVON	[2020/18]
	English:	HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF	[2020/18]
	French:	INHIBITEURS DE KINASE HÉTÉROCYCLIQUES ET LEURS UTILISATIONS	[2020/18]
Examination procedure	29.10.2020	Amendment by applicant (claims and/or description)
	29.10.2020	Examination requested [2020/50]
	29.10.2020	Date on which the examining division has become responsible
	20.01.2022	Despatch of a communication from the examining division (Time limit: M06)
	01.08.2022	Reply to a communication from the examining division
	13.06.2023	Despatch of a communication from the examining division (Time limit: M04)
	23.10.2023	Reply to a communication from the examining division
Fees paid	Renewal fee
	14.10.2020	Renewal fee patent year 03
	26.10.2021	Renewal fee patent year 04
	28.09.2022	Renewal fee patent year 05
	26.10.2023	Renewal fee patent year 06
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[A]WO2006081172 (IRM LLC [US], et al) [A] 1-20 * claim -; table 1 *;
		[A]WO2008033746 (CURIS INC [US], et al) [A] 1-20* claim - *
	by applicant	US4439196
		US4447233
		US4447224
		US4475916
		US4486194
		US4487603
		US4522811
		US4596556
		US4790824
		US4941880
		US5064413
		US5312335
		US5374548
		US5383851
		US5399163
		US5399331
		US5416016
		US2011318373
		- ARAUJO et al., Lancet Oncol., (20130000), vol. 14, page 13017
		- ARAUJO et al., Cancer, (20120000), vol. 118, page 63
		- EVENS et al., Annal. Onc., (20170000), vol. 28, page 354
		- The Targeted Agent and Profiling Utilization Registry, URL: https://www.tapur.org, NCT02693535
		- ROSSARI; ORCIUOLO, J. Hemat. Oncol., (20180000), vol. 11, page 84
		- JABBOUR et al., Leukemia, (20060000), vol. 20, page 1767
		- MANLEY et al., Biochem. Biophys. Acta, (20050000), vol. 1754, page 3
		- HUGHES et al., Leukemia, (20150000), vol. 29, page 1832
		- NICOLINI et al., Blood, (20090000), vol. 114, page 5271
		- BANTSCHEFF et al., Nat. Biotech., (20070000), vol. 25, page 1035
		- ANASTASSIADIS et al., Nat. Biotech., (20120000), vol. 29, page 1039
		- OZANNE et al., Biochem. J., (20150000), vol. 465, page 271
		- WEI et al., J. Hemat. Oncol., (20100000), vol. 3, page 47
		- BABEI et al., Drug Des. Dev. Thera., (20160000), vol. 10, page 2443
		- WOODMAN et al., J. Clin. Onc., (20090000), vol. 27, page 9019
		- GALANIS; LEVIS, Haematologica, (20150000), vol. 100, page e89
		- KATOH et al., Mol. Cell. Endocrinol., (20040000), vol. 217, page 109
		- WEIN et al., Nature Commun., (20160000), vol. 7, page 13176
		- SELVIK et al., PLoS ONE, (20140000), vol. 9, page e112485
		- Pharmacological/Toxicity Review and Evaluation of NDA 21-986, page 31
		- MANNING et al., Science, (20021206), vol. 298, no. 5600, pages 1912 - 1934
		- BERGE et al., "Pharmaceutical Salts", J. Pharm. Sci., (19770000), vol. 66, doi:doi:10.1002/jps.2600660104, pages 1 - 19, XP002675560 DOI: http://dx.doi.org/10.1002/jps.2600660104
		- STREJAN et al., J. Neuroimmunol., (19840000), vol. 7, page 27
		- V.V. RANADE, J. Clin. Pharmacol., (19890000), vol. 29, page 685
		- UMEZAWA et al., Biochem. Biophys. Res. Commun., (19880000), vol. 153, page 1038
		- P.G. BLOEMAN et al., FEBS Lett., (19950000), vol. 357, page 140
		- M. OWAIS et al., Antimicrob. Agents Chemother., (19950000), vol. 39, page 180
		- BRISCOE et al., Am. J. Physiol., (19950000), vol. 1233, page 134
		- YANG et al., Blood, (20120000), vol. 120, page 4533
		- DENG et al., Hybrid Hybridomics, (20040000), vol. 23, page 176
		- LOWE et al., Oncoimmunology, (20140000), vol. 3, page e27589
		- "UniProt", Database accession no. Q9Y2K2
		- LIZCANO, J. M. et al., EMBO J., (20040000), vol. 23, pages 833 - 843
		- TATUSOVA; MADDEN, FEMS Microbiol Lett, (19990000), vol. 174, pages 247 - 250
		- "UniProt", Database accession no. P57059
		- "UniProt", Database accession no. Q9HOKI
		- PENNICA et al., Nature, (19840000), vol. 312, pages 724 - 9
		- "UniProtKB/Swiss-Prot", Database accession no. P01375
		- "UniProtKB/Swiss-Prot", Database accession no. Q06599
		- "UniProtKB/Swiss-Prot", Database accession no. P51742
		- "UniProtKB/Swiss-Prot", Database accession no. P13296
		- "UniProtKB/Swiss-Prot", Database accession no. P51435
		- "UniProtKB/Swiss-Prot", Database accession no. P19101
		- "UniProtKB/Swiss-Prot", Database accession no. P29553
		- "UniProtKB/Swiss-Prot", Database accession no. P06804
		- "UniProtKB/Swiss-Prot", Database accession no. Q8HZD9
	- "UniProtKB/Swiss-Prot", Database accession no. P23563
	- "UniProtKB/Swiss-Prot", Database accession no. P04924
	- "UniProtKB/Swiss-Prot", Database accession no. P16599
	- SMITH; BAGLIONI, J Biol Chem, (19870000), vol. 262, pages 6951 - 4
	- KRIEGLER et al., Cell, (19880000), vol. 53, pages 45 - 53
	- FLICK; GIFFORD, J Immunol Methods, (19840000), vol. 68, pages 167 - 75
	- DOBRZYCKA et al., Eur Cytokine Netw, (20090000), vol. 20, page 131
	- AYDIN et al., Turk J Med Sci, (20120000), vol. 42, page 762
	- REISSFELDER et al., J Clin Inv, (20150000), vol. 125, page 739
	- WANG; LIN, Acta Pharmacol Sin, (20080000), vol. 28, page 1275
	- FERRERO et al., Am J Physiol Cell Physiol, (20010000), vol. 281, page C1173
	- ETEMADI et al., FEBS J, (20130000), vol. 280, page 5283
	- BERNT et al., Cancer Res, (20050000), vol. 65, page 4343
	- KAUFMAN et al., Nature Rev Drug Disc, (20150000), vol. 14, page 642
	- SONG et al., Oncotarget., (20150000), vol. 6, page 21533
	- FOGLIETTA et al., Bone Marrow Transplant, (20130000), vol. 48, page 269
	- ZHU et al., Biomed Pharmacother, (20090000), vol. 63, page 509
	- REDMOND et al., Cancer Immunol Res., (20140000), vol. 2, page 142
	- MAUTE, PNAS, (20150000), vol. 112, page E6506
	- CHANG et al., Anyeg Chem Int, (20150000), vol. 54, page 11760
	- ZAK et al., Oncotarget, (20160000), vol. 7, page 30323
	- SKALNIAK et al., Oncotarget, (20170000), vol. 8, page 72167
	- POWDERLY, Ann One, vol. 28, no. 5
	- KARAMAN et al., Nat Biotech, (20080000), vol. 26, page 127
	- KHANDELWAL et al., EMBO Mol Med, (20150000), vol. 7, page 540
	- GIBBONS et al., PNAS, (20140000), vol. 111, page 3550
	- DONATO et al., Cancer Res, (20040000), vol. 64, page 672
	- WU et al., Leukemia, (20100000), vol. 24, page 869
	- LIU et al., Cancer Cell, (20100000), vol. 17, page 333
	- PUTTINI et al., Cancer Res, (20060000), vol. 66, page 11314
	- FAUVEL et al., Am J Can Sci, (20130000), vol. 2, page 28
	- HEKIM et al., Can Imm Res, (20170000), vol. 5, page 157
	WO2018EP60172

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 35p